Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
JULUCA (ViiV Healthcare Pty Ltd)
Product name
JULUCA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
169 working days (255)
Active ingredients
rilpivirine hydrochloride; dolutegravir
Registration type
EOI
Indication
New combination
JULUCA (tablets) is now also indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor.